Overview
Masayuki Fujinaga practices practicing medicine in Inage, Japan.
His clinical expertise encompasses Melanoma, Cerebral Hypoxia, Dementia, and Nonalcoholic Steatohepatitis (NASH).
He is actively involved in clinical research, co-authoring 111 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Masayuki Fujinaga
Is Masayuki Fujinaga a top-rated expert for Melanoma?
MediFind is an objective health platform that identifies experts based on real-world data. Masayuki Fujinaga is classified as an Experienced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Masayuki Fujinaga participate in research or clinical trials?
Yes. Masayuki Fujinaga has published 111 articles and abstracts on conditions like Melanoma. You can view a list of Masayuki Fujinaga's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cerebral HypoxiaMr. Fujinaga isExperienced. Learn about Cerebral Hypoxia.
- DementiaMr. Fujinaga isExperienced. Learn about Dementia.
- MelanomaMr. Fujinaga isExperienced. Learn about Melanoma.
- Nonalcoholic Steatohepatitis (NASH)Mr. Fujinaga isExperienced. Learn about Nonalcoholic Steatohepatitis (NASH).